Dalcetrapib: Turning the tide for CETP inhibition?

The Lancet

Volumn 378, Issue 9802, 2011, Pages 1529-1530

  Stroes, Erik S G ^a   Van Wijk, Diederik F ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; FLUORODEOXYGLUCOSE F 18; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TORCETRAPIB;

ATHEROGENESIS; ATHEROSCLEROSIS; CONCENTRATION (PARAMETERS); HUMAN; ISCHEMIC HEART DISEASE; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 80255122639     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61421-9     Document Type: Note

References (13)

1. L Camont, MJ Chapman, A Kontush Biological activities of HDL subpopulations and their relevance to cardiovascular disease Trends Mol Med 2011 10.1016/j.molmed.2011.05.013 published online Aug 11.
2. PJ Barter, M Caulfield, M Eriksson for the ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122 (Pubitemid 350146106)
3. DJ Rader Illuminating HDL - is it still a viable therapeutic target? N Engl J Med 357 2007 2180 2183 (Pubitemid 350146114)
4. ZA Fayad, V Mani, M Woodward for the dal-PLAQUE Investigators Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial Lancet 2011 10.1016/S0140-6736(11)61383-4 published online Sept 12.
5. X Hu, JD Dietz, C Xia et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition Endocrinology 150 2009 2211 2219
6. ES Stroes, JJ Kastelein, A Benardeau et al. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin- aldosterone system in rats Br J Pharmacol 158 2009 1763 1770
7. R Sofat, AD Hingorani, L Smeeth et al. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms Circulation 121 2010 52 62
8. M Vergeer, ML Bots, SI van Leuven et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) trials Circulation 118 2008 2515 2522
9. EA Stein, ES Stroes, G Steiner et al. Safety and tolerability of dalcetrapib Am J Cardiol 104 2009 82 91
10. JJ Kastelein, SI van Leuven, L Burgess et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 2007 1620 1630 (Pubitemid 46631671)
11. CP Cannon, S Shah, HM Dansky et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
12. JH Rudd, F Hyafil, ZA Fayad Inflammation imaging in atherosclerosis Arterioscler Thromb Vasc Biol 29 2009 1009 1016
13. P Libby, PM Ridker, GK Hansson Progress and challenges in translating the biology of atherosclerosis Nature 473 2011 317 325